were randomized to one of the following age-and sex-matched groups: 1) the control group (n ϭ 25); 2) the exercise group (n ϭ 25), who underwent 8 months' exercise training; 3) the rosiglitazone group (n ϭ 25), who had adjunctive therapy with 8 mg/day rosiglitazone; and 4) the rosiglitazone plus exercise (RSG ϩ EX) group (n ϭ 25), who participated in the 8-month exercise program (as in the exercise group) while simultaneously receiving treatment with 8 mg/day rosiglitazone.
The prescription of the exercise program was based on initial ergocycle testing results. Afterward, its workload was gradually increased until patients achieved 50 -80% VO 2max during 45-60 min sessions four times a week (5) . After the fourth week, the intensity and duration of each session remained constant. Patients of the control and rosiglitazone groups were instructed to maintain their habitual activities.
Laboratory and clinical measurements
Blood samples were obtained at baseline and at the end of the study. All participants avoided any severe physical activity 48 h before measurements. Plasma adiponectin (R&D Systems), resistin (BioVendor Laboratory Medicine, Modrice, Czech Republic), insulin (DRG Diagnostics, Marburg, Germany), and IL-6 and TNF-␣ (Assay Designs) concentrations were assayed using enzyme-linked immunosorbent assay kits. The intra-and interassay coefficients of variation are provided by manufacturers. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR) (6) . Samples were frozen and stored (Ϫ80°C) until analysis in the same assay. Cardiorespiratory capacity was assessed at baseline and at the end of the study with a graded symptom-limited exercise test on an electronically-braked ergocycle, using a gas-exchange analyzer (COSMED K4; COSMED, Rome, Italy) (7).
Statistical analysis
Comparison between groups of baseline and final values and changes of variables was performed by one-way ANOVA and post hoc Tukey test (2 ϫ 2 factorial design). Changes within groups were analyzed by Wilcoxon's signed-rank test. Normality of distribution was assessed by Kolmogorov-Smirnov test. A P value of Ͻ0.05 was considered statistically significant.
RESULTS

Interventions effects
Baseline values of all variables and the concomitant medications did not differ between groups. Five patients discontinued the study because of personal reasons. In the end, 95 patients were eligible for analysis. No adverse events were reported.
Compared with that at baseline and in the exercise group, rosiglitazone treatment increased BMI significantly (P Ͻ 0.001). No substantial changes were noted in the other groups. Exercise training increased exercise capacity (VO 2max ) by 14.9% (P Ͻ 0.001), while rosiglitazone induced a modest (5.46%) but significant improvement in fitness compared with that both at baseline (P Ͻ 0.001) and in the control group (P ϭ 0.031). Importantly, combined therapy remarkably increased VO 2max (26.48%; P Ͻ 0.001), which exceeded the complementary effects of both interventions.
Although both rosiglitazone treatment and exercise training alone ameliorated glycemic indexes, fasting insulin, and HOMA-IR (P Ͻ 0.05), the RSG ϩ EX group elicited a more pronounced decrease of the aforementioned parameters compared with that of all of the other groups (P Ͻ 0.05) ( Table 1) .
Adipocytokines
We observed considerable reduction of resistin and IL-6 levels in all of the interventions groups (P Ͻ 0.05), but greater alterations were found in the RSG ϩ EX group. Both combined therapy and rosiglitazone treatment alone elicited significant increments of adiponectin in comparison with baseline values and the changes elicited by other groups (P Ͻ 0.05). Similarly, TNF-␣ was also downregulated significantly in the latter groups, and, compared with that in the control group, the change was significant only after combined treatment. Patients in the exercise group demonstrated a slight increase of adiponectin (P ϭ 0.39) and a less marked decrease of TNF-␣ (P ϭ 0.45). No adipocytokines were affected significantly in the control group.
CONCLUSIONS -In this 8-month study, we demonstrated for the first time that simultaneous treatment with rosiglitazone plus exercise attenuated adipocytokine levels, counteracted rosiglitazoneinduced weight gain, and extended improvements of insulin sensitivity, glycemic control, and fitness beyond those expected by their complementary actions in patients with type 2 diabetes.
The most pronounced results of glucose regulation were observed in the RSG ϩ EX group (A1C Ϫ19.1%). After completion of the study, 78% of patients in the RSG ϩ EX, 37.9% in the rosiglitazone, and 21.82% in the exercise group had achieved glycemic target (A1C Ͻ7%). This is a striking finding in that our patients had inadequate glycemic control notwithstanding the double antidiabetes treatment. Furthermore, combined treatment considerably ameliorated insulin resistance (change of HOMA-IR [␦HOMA-IR] Ϫ68.1%), exceeding the expected results from the addition of rosiglitazone (␦HOMA-IR Ϫ30.8%) to exercise (␦HOMA-IR Ϫ23.08%). We hypothesized that the latter synergistic effects might be ascribed to multiple interactions be- Data are means Ϯ SEM unless otherwise indicated. *Levels of variables between baseline and the end of the study within groups; †post hoc analysis of changes of variables between groups; ‡P Ͻ 0.001; §RSG ϩ EX vs. control group; ¶rosiglitazone vs. control group; ʈexercise vs. control group; **RSG ϩ EX vs. exercise group; † †RSG ϩ EX vs. rosiglitazone group; ‡ ‡P Ͻ 0.05; § §rosiglitazone vs. exercise group. P 1 , ANOVA of changes of variables between groups. FPG, fasting plasma glucose; NS, not significant.
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Poor metabolic control, physical inactivity, and muscle abnormalities are determinants of impaired exercise capacity in type 2 diabetes (1,10). To our knowledge, this is the first study demonstrating a robust increase of fitness in the RSG ϩ EX group, outlining synergism between thiazolidinediones and exercise training. Trying to explain these results, we observed that the VO 2max increment was correlated with HOMA-IR and A1C reduction in all active groups (data not shown). We then postulated that metabolic control improvement after combined treatment might amplify VO 2max elevation. Alternatively, thiazolidinediones and physical activity have been demonstrated to ameliorate endothelial dysfunction and induce mitochondrial biogenesis and thereby could facilitate oxygen delivery and muscle performance (1, 11, 12) .
Adiponectin modulates insulin sensitivity with significant antiatherogenic properties (13) . Our lifestyle intervention left adiponectin levels almost unaltered, while rosiglitazone treatment doubled adiponectin levels (14) . Therefore, the increment of adiponectin in the RSG ϩ EX group was predominantly ascribed to rosiglitazone administration.
Up to now, limited studies have provided conflicting data about the influence of thiazolidinediones and prolonged exercise on human plasma adipocytokines (5, (15) (16) (17) (18) (19) . We demonstrated that all interventions suppressed resistin and IL-6 levels, while both combined therapy and rosiglitazone treatment alone decreased TNF-␣ levels significantly. Those effects were independent of insulin resistance modulation. Among all groups, the greatest magnitude of anti-inflammatory impact was found in the RSG ϩ EX group, which raises the prospect of reduced cardiovascular risk.
Weight gain, the most common side effect of thiazolidinediones, is predominantly attributed to fluid retention (3). In the RSG ϩ EX group, body weight remained stable. Perhaps the addition of exercise counterbalanced the rosiglitazonerelated body weight increase by remarkably decreasing fat mass content.
The principal limitation of our study was the small number of patients. However, the sample cohort was adequately homogeneous. Another limitation was the usage of the HOMA-IR index. Although it is dependent on both peripheral and hepatic insulin sensitivity, it highly correlates with estimation derived from the euglycemic clamp test (6) . The combination of rosiglitazone and exercise favored remarkable benefits on traditional and novel cardiovascular risk factors. Further research will confirm the aforementioned promising results.
